A New Era of Immunotherapy in Small-Cell Lung Cancer
  • CME

Watch this CME-certified video module of 2 lung cancer experts discussing recent advances in immunotherapy for the treatment of SCLC as they apply to a series of patient cases.
Anna F. Farago, MD, PhD
Leora Horn, MD, MSc, FRCPC
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Released: August 8, 2019 Expiration: August 7, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate the available efficacy and safety data on immunotherapies and their clinical implications for current therapy decisions in patients with SCLC at all disease stages
  • Plan treatment strategies for patients with SCLC that include immune checkpoint inhibitors
  • Differentiate the mechanisms of action and clinical properties of antibody–drug conjugates and other targeted therapies for the treatment of patients with SCLC

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Anna F. Farago, MD, PhD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Assistant in Medicine
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Anna F. Farago, MD, PhD, has disclosed that she has received funds for research support from AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Loxo, Merck, and PharmaMar and consulting fees from AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Genentech, and Loxo.
Leora Horn, MD, MSc, FRCPC

Ingram Associate Professor of Cancer Research
, Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt Ingram Cancer Center
Nashville, Tennessee

Leora Horn, MD, MSc, FRCPC, has disclosed that she has received consulting fees from AstraZeneca, EMD Serono, Genentech, Incyte, Merck, and Xcovery and funds for research support from Boehringer Ingelheim, Bristol-Myers Squibb, and Xcovery.


Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Taryn O'Loughlin Gross, PhD

Editorial Contributor

Taryn O’Loughlin Gross, PhD, has disclosed that she has received fees for non-CME/CE services from Harmony Biosciences, Shionogi, and Soluda Medical.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with small-cell lung cancer.


The goal of this activity is to improve participants’ preparedness to integrate novel immunotherapies and targeted agents into the treatment of patients with small-cell lung cancer.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 08, 2019, through August 07, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Data presented at ASCO 2020 of a pooled biomarker analysis of the MONALEESA phase III trials evaluating ribociclib sensitivity in breast cancer

Released: May 31, 2020

Results from DESTINY-Lung01 of trastuzumab deruxtecan (T-DXd) in previously treated NSCLC with HER2 mutation, from ASCO 2020 as reported by CCO.

Released: May 30, 2020

Thomas Bachelot, MD, PhD, provides insights on managing HER2-positive metastatic breast cancer with new therapies in this slideset from Clinical Care Options.

Thomas Bachelot, MD, PhD Released: May 29, 2020

Download these slides with insights on MET as a new molecular target in lung cancer care, including guidance on testing for METex14 mutations, from CCO

person default Luis Paz-Ares, MD, PhD Released: May 29, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?